Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT05359692 is registered in ClinicalTrials.gov with Incyte Biosciences International Sàrl as lead sponsor.

NCT NCT05359692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05359692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
Incyte Biosciences International Sàrl
Phase
Phase 2
Overall status
Withdrawn
Start date
March 1, 2023
Completion date
January 11, 2025
Enrollment
0 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, metastatic head and neck squamous cell carcinoma, recurrent head and neck squamous cell carcinoma